Probiotics may provide relief for infants with colic, new study reveals

Press releases   •   Dec 04, 2019 10:01 UTC

Up to one in four infants globally suffer from excessive crying and fussing – often called colic. A new study shows that the BB-12® probiotic strain may help reduce crying duration and the number of crying episodes and bring relief to infants and their parents

Probiotics may help preterm infants

Press releases   •   Nov 28, 2019 08:51 UTC

A new three-strain probiotic blend from Chr. Hansen can help support the health and development of intestines in preterm babies and has been shown to reduce risk of Necrotizing enterocolitis by 50%

Chr. Hansen’s Head of Sustainability recognized as Meaningful Business 100 Leader

Press releases   •   Nov 06, 2019 12:09 UTC

Global platform brings together the top 100 business leaders who are combining profit and purpose to help achieve the UN Sustainable Development Goals

Chr. Hansen reaches 7% organic growth in 2018/19

Press releases   •   Oct 10, 2019 06:28 UTC

Despite more challenging growth conditions Chr. Hansen delivers a strong EBIT margin and a healthy cash flow, while also making significant progress on key strategic priorities

Chr. Hansen’s good bacteria to be produced on solar power

Press releases   •   Sep 23, 2019 08:07 UTC

A new 10-year agreement enables Chr. Hansen Denmark to switch 100% to green power from two brand new solar parks. The agreement underlines Chr. Hansen’s commitment to a sustainable future and will create more green energy capacity to the benefit of all of Denmark.

Chr. Hansens gode bakterier skal fremstilles på solenergi

Press releases   •   Sep 23, 2019 08:02 UTC

En ny tiårig aftale med Better Energy betyder, at Chr. Hansen kan overgå 100% til grøn strøm fra to helt nye solcelleparker. Aftalen understreger Chr. Hansens dedikation til en bæredygtig fremtid og skaber mere grøn energi til hele Danmark.

Chr. Hansen and Lonza’s newly branded joint venture, BacThera, receives anti-trust approvals to start contract manufacturing of live biotherapeutic products

Press releases   •   Aug 29, 2019 13:52 UTC

​Chr. Hansen Holding A/S, a leading global bioscience company, and Lonza AG, a leading pharma contract manufacturing company, announce today that they have received the relevant approvals from anti-trust regulators needed to establish the 50/50 joint venture in the emerging market for live biotherapeutic products, which was originally announced in Company Announcement No. 04 on April 2, 2019.

Chr. Hansen and Lonza’s newly branded joint venture, BacThera, receives anti-trust approvals to start contract manufacturing of live biotherapeutic products

News   •   Aug 29, 2019 09:16 UTC

​Chr. Hansen Holding A/S, a leading global bioscience company, and Lonza AG, a leading pharma contract manufacturing company, announce today that they have received the relevant approvals from anti-trust regulators needed to establish the 50/50 joint venture in the emerging market for live biotherapeutic products, which was originally announced in Company Announcement No. 04 on April 2, 2019.

Chr. Hansen gearer op til en bæredygtig fremtid

Press releases   •   Aug 29, 2019 07:39 UTC

Den globale bioscience virksomhed udvider og styrker forskning- & udviklingsfaciliteterne i Hørsholm for at imødekomme den stigende efterspørgsel efter naturlige og bæredygtige produkter.

Chr. Hansen gears up for a sustainable future

Press releases   •   Aug 29, 2019 07:38 UTC

Global bioscience company Chr. Hansen to expand and strengthen its research & development facilities north of Copenhagen to meet the increasing demand for natural and sustainable products.

Contacts 6 contacts

  • Press Contact
  • Head of Media Relation
  • DKarCAfgLEts@cdwhryj-hxvanlzsemyn.xecoxwmne
  • +45 53 39 23 84
  • +45 45 74 76 42

  • Press Contact
  • Press officer
  • DKjaHRwiE@richbcr-vghamvnseaenuc.csmomhw
  • +45 45 74 76 36
  • +45 20 74 28 40

About Chr. Hansen A/S

About us

Chr. Hansen is a leading, global bioscience company that develops natural solutions for the food, nutritional, pharmaceutical and agricultural industries. We develop and produce cultures, enzymes, probiotics and natural colors for a rich variety of foods, confectionery, beverages, dietary supplements, animal feed, and plant protection. Our product innovation is based on around 40,000 microbial strains – we like to refer to them as “good bacteria”. Our solutions enable food manufacturers to produce more with less – while also reducing the use of chemicals and other synthetic additives – which makes our products highly relevant in today’s world. Sustainability is an integral part of Chr. Hansen’s vision to improve food and health. In 2019 Chr. Hansen was ranked as the world’s most sustainable company by Corporate Knights thanks to our strong sustainability efforts and our many collaborative partnerships with our customers. We have been delivering value to our partners – and, ultimately, end consumers worldwide – for over 145 years. We are proud that more than one billion people consume products containing our natural ingredients every day. Chr. Hansen was founded in 1874 and is listed on Nasdaq Copenhagen.

Address

  • Chr. Hansen A/S
  • Boege Allé 10-12
  • DK-2970 Hoersholm
  • Denmark